Clinical Trials Logo

Filter by:
NCT ID: NCT05861362 Completed - Breast Cancer Clinical Trials

Feasibility and Metabolic Effects of a 5:2 Fasting Intervention in Women With Breast Cancer During Radiotherapy

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The intervention consists of the adoption of a 5:2 intermittent fasting diet during radiotherapy of breast cancer patients. The aim of the study was to assess the feasibility of this intervention and its impact on body composition and selected metabolic blood parameters.

NCT ID: NCT05857345 Completed - Micronutrients Clinical Trials

Breastmilk as a Source of Lactocytes

Start date: April 28, 2023
Phase:
Study type: Observational

The objective of this study is to determine the suitability of lactocytes derived from human breast milk for gene expression analysis, and to explore whether there are any correlations between gene expression and the micronutrient composition of breast milk.

NCT ID: NCT05853445 Completed - Polycythemia Vera Clinical Trials

A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera

PAVE
Start date: August 17, 2015
Phase:
Study type: Observational

Jakavi® therapy for polycythemia vera (PV) has so far been studied exclusively in clinical trials and at selected clinical trial centres. This observational study is intended to document the therapy of PV in daily practice with a broad patient population and a geographically representative selection of German centres (both hospitals and practices). The prospective mapping of daily practice reality is thus the main goal of this project.

NCT ID: NCT05853341 Completed - Healthy Clinical Trials

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)

Start date: May 2, 2023
Phase: Phase 1
Study type: Interventional

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 13.3 mg/24 h (Luye Pharma AG, Germany) and the marketed Reference product Exelon® 13.3 mg/24 h transdermales Pflaster (Novartis Pharma GmbH, Germany) after multiple patch applications. Each of both treatments will last for 11 days with a washout period of 14 days between the treatments.

NCT ID: NCT05853328 Completed - BPPV Clinical Trials

Comparison of EM and SM+ Maneuvers in Patients With BPPV

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Objective of this prospective randomized treatment trial is to compare the effectiveness of the SemontPLUS (SM+) with the Epley maneuver (EM) for the therapy of posterior canal benign paroxysmal positional vertigo canalolithiasis (pcBPPV).

NCT ID: NCT05851469 Completed - Diabetes Mellitus Clinical Trials

Study of a Non-invasive Glucose Measuring Device

Start date: May 31, 2023
Phase: N/A
Study type: Interventional

This explorative clinical investigation has been launched to collect spectral Raman data paired with validated glucose reference values in persons with diabetes.

NCT ID: NCT05842759 Completed - Anesthesia Clinical Trials

Avoiding Postinduction Hypotension: the Clinical ZERO-HYPOTENSION Proof-of-concept Study

Start date: March 7, 2023
Phase: N/A
Study type: Interventional

In this clinical proof-of-concept study, the aim is to investigate the efficacy of a hypotension avoidance strategy to prevent post-induction hypotension. Specifically, it will be investigate how much postinduction hypotension occurs when using a hypotension avoidance strategy - combining continuous intraarterial blood pressure monitoring, careful administration of anesthetic drugs, and continuous administration of norepinephrine to treat hypotension - in high-risk patients having elective non-cardiac surgery.

NCT ID: NCT05842421 Completed - Clinical trials for Non-melanoma Skin Cancer

Imaging Methods for the Diagnosis of Non-melanoma Skin Cancer and Its Precursors

Start date: April 21, 2021
Phase: N/A
Study type: Interventional

Prospective, unicentric study that examines if imaging devices like total body photography, dermoscopy, optical coherence tomography and in vivo reflectance confocal microscopy as an addition to clinical examination lead to a benefit for patients in the diagnosis of non-melanoma skin cancer and their precursors

NCT ID: NCT05840848 Completed - Bioavailability Clinical Trials

Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males

Start date: November 21, 2017
Phase: N/A
Study type: Interventional

In vitro studies found supplemental levels of iron and zinc to inhibit the micellization and cellular uptake of β-carotene. Here, we investigated this in vivo, in a double-blind 3-arm crossover human trial. Healthy males (n=6) ingested, with breakfast, a single dose of 15 mg β-carotene in combination with either a placebo, 25 mg iron or 30 mg zinc capsule. Blood samples were collected at baseline and hourly for 10 hours. The triacylglycerol-rich fraction (TRF) was analysed for concentrations of β-carotene and plasma for β-carotene, retinol, triacylglycerols, LDL- and HDL-cholesterol.

NCT ID: NCT05836428 Completed - Clinical trials for Post-COVID-19 Syndrome

Biomarker Analysis in Post-COVID Patients

Start date: August 1, 2020
Phase:
Study type: Observational

Headache is one of the most common neurological manifestations of COVID-19. However, it is unclear whether chronic headache after the initial diagnosis, is associated with ongoing damage of the central nervous system. We investigate cpost-COVID-19 patients with persistent headache lasting longer than 3 weeks, to hospitalized acute COVID-19 patients with neurological symptoms and to other non-COVID-19 disease-controls. Readout are neurologial and glial biomarkers in CSF.